权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Genome Integrity in Candida albicans

白色念珠菌的基因组完整性

基本信息

批准号：
7370982
负责人：
Judith G. Berman
金额：
$ 34.2万
依托单位：
UNIVERSITY OF MINNESOTA
依托单位国家：
美国
项目类别：
财政年份：
2005
资助国家：
美国
起止时间：
2005-06-01 至 2010-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7370982
关键词：
Acquired Immunodeficiency Syndrome Alleles Aneuploidy Antifungal Agents Azole resistance Azoles Candida Candida albicans Candidiasis Cause of Death Cells Chromosomes Chromosomes, Human, Pair 1 Class Clinical Companions Complication Condition Coupled DNA Microarray Chip DNA Microarray format Drug resistance Drug-sensitive Esophageal Event Exhibits Fluconazole Fluconazole resistance Frequencies Genes Genetic Recombination Genome Genomic Instability Genomics Genotype Goals Growth HIV Human Hybridization Array In Vitro Infection Laboratories Loss of Heterozygosity Measures Microarray Analysis Molecular Monitor Mus Mutation Numbers Opportunistic Infections Oropharyngeal Patients Pharmaceutical Preparations Physiological Prevalence Range Rate Research Research Personnel Single Nucleotide Polymorphism Site Stress Testing candidemia comparative genomic hybridization improved in vivo mutant oropharyngeal thrush pathogen programs tool

项目摘要

DESCRIPTION (provided by applicant): Opportunistic infections remain the most important complication of infection with the Human Immunodeficiency Virus (HIV) and the principal cause of death in patients with the Acquired Immune Deficiency Syndrome (AIDS). A large proportion of these patients develop severe oropharyngeal and esophageal candidiasis and treatment with the azole class of anti-fungal drugs such as fluconazole, has led to an increase in the prevalence of azole-resistant Candida strains. Many drug-resistant strains exhibit genetic alterations including changes in chromosome copy number (aneuploidy) and loss of heterozygosity at genes important for drug resistance. Our long-term goal is to understand whether Candida albicans genome instability facilitates its adaptation to stresses encountered in the human host and, if it does, to determine the molecular mechanisms by which it does so. We will use three powerful tools to analyze genetic changes across the entire C. albicans genome will be used: Single Nucleotide Polymorphism (SNP) arrays will monitor loss of heterozygosity events throughout the C. albicans genome; Comparative Genome Hybridization arrays will detect the toss or gain of whole chromosomes or chromosome fragments (aneuploidy); And the counter-selectable GAL1 gene will be used to isolate rare loss of heterozygosity events in vivo and in vitro. Preliminary results indicate that the SNP arrays readily distinguish homozygous and heterozygous genotypes, that the Comparative Genome Hybridization arrays accurately detect increases and decreases in chromosome copy number, that recombination frequency in C. albicans cells is elevated when cells are propagated in vivo and that loss of heterozygosity and/or aneuploidy occurs in strains that exhibit increased levels of drug resistance or increased ability to colonize the host. In this proposal, we will test the hypothesis that C. albicans responds to stresses it encounters in the host and/or when exposed to antifungal drugs with increased levels of aneuploidy and/or loss of heterozygosity. Further, we will ask if specific genome changes provide C. albicans a selective advantage under these stress conditions. We will detect aneuploidy and loss of heterozygosity in fluconazole resistant strains, measure the frequency, rates and types of loss of heterozygosity events that occur, and will identify specific genome segments and genes necessary for fluconazole resistance. Our proposed research has the potential to make two unique contributions. Specific pathogen genotypes that have a higher potential to become drug resistant may be identified, improved strategies for preserving the efficacy of existing antifungal agents through the use of companion drugs or therapies may be discovered.

描述（由申请人提供）：机会性感染仍然是人类免疫缺陷病毒（HIV）感染最重要的并发症，也是获得性免疫缺陷综合征（AIDS）患者死亡的主要原因。这些患者中很大一部分发展为严重的口咽和食管念珠菌病，使用氟康唑等唑类抗真菌药物治疗，导致耐唑念珠菌菌株的患病率增加。许多耐药菌株表现出遗传改变，包括染色体拷贝数的改变（非整倍性）和对耐药重要基因的杂合性丧失。我们的长期目标是了解白色念珠菌基因组的不稳定性是否有助于其适应人类宿主遇到的压力，如果确实如此，则确定其分子机制。我们将使用三种强大的工具来分析整个白色念珠菌基因组的遗传变化：单核苷酸多态性（SNP）阵列将监测整个白色念珠菌基因组的杂合性损失事件；比较基因组杂交阵列将检测整个染色体或染色体片段（非整倍体）的损失或增益；反选择性GAL1基因将用于分离体内和体外罕见的杂合性缺失事件。初步结果表明，SNP阵列容易区分纯合子和杂合子基因型，比较基因组杂交阵列准确检测染色体拷贝数的增加和减少，当细胞在体内繁殖时，白色念珠菌细胞的重组频率升高，杂合子和/或非整倍体的丧失发生在表现出更高水平的耐药性或增强的定植宿主能力的菌株中。在本提案中，我们将验证白色念珠菌对宿主和/或暴露于抗真菌药物的应激反应的假设，即非整倍体水平增加和/或杂合性丧失。此外，我们将询问特定的基因组变化是否在这些压力条件下为白色念珠菌提供了选择优势。我们将检测氟康唑耐药菌株的非整倍性和杂合性丧失，测量发生的杂合性丧失事件的频率、速率和类型，并将确定氟康唑耐药所需的特定基因组片段和基因。我们提出的研究有可能做出两个独特的贡献。可能会发现具有更高耐药潜力的特定病原体基因型，可能会发现通过使用伴随药物或疗法来保持现有抗真菌药物功效的改进策略。